Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1 st and 2 nd doses of the BNT162b2 vaccineBNT162b2 백신의 1차 및 2차 접종 후 역학 및 임상 특성을 갖는 총 및 중화 SARS-CoV-2 스파이크 수용체 결합 도메인 항체의 연관성Article Published on 2021-09-242022-09-11 Journal: Vaccine [Category] SARS, 진단, 치료기술, [키워드] age antibody antibody levels association binding domain BMI BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine BNT162b2 vaccine Clinical characteristics clinical parameter Clinical parameters Cohort correlation COVID-19 COVID-19 vaccine dose elicited epidemiological females Final groups healthcare worker Immunity immunization Immunosuppressive medication immunosuppressive medications IQR median NAbs negatively affected Neutralizing Neutralizing antibodies neutralizing antibody Older age participant positive Protective Protein RBD Receptor binding domain SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein second dose significant difference smoking Spearman spike Spike protein statistical analysis statistically significant systemic adverse event systemic adverse events the vaccine vaccine dose vaccine doses was performed [DOI] 10.1016/j.vaccine.2021.07.067 PMC 바로가기 [Article Type] Article
Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2Article Published on 2021-09-172022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Administered administration antibody antibody levels Antibody Response Asymptomatic BNT162b2 BNT162b2 mRNA collected Concentration COVID-19 domain dose effective evaluate Evaluating first dose greater healthcare worker infected with SARS-CoV-2 Infection Italy majority of BNT162b2 positive RBD reached receiving response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 testing second dose Spike protein statistically significant difference subject subjects Total two groups vaccination Vaccine virus were measured worker [DOI] 10.3390/jcm10184204 PMC 바로가기 [Article Type] Article
Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion혈청전환 전 COVID-19 환자에서 외래 환자 유래 COVID-19 회복기 혈장의 사용Immunology Published on 2021-09-142022-09-11 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] ACE2 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibodies antibody antibody levels Antibody titer Antibody titers antiviral antibodies binding CCP collected convalescence convalescent plasma convalescent plasma for COVID-19 therapy Course COVID-19 COVID-19 patient COVID-19 patients detectable disease course Donor donors early response Effect ELISA estimate Factor Fever high-titer CCP highest humoral immune response identify in viral in vitro lesson magnitude Mild disease much lower N-protein pandemic Pandemics patients pharmacokinetic plasma RBD RBD-ACE2 recipients resource Result RNA SARS-CoV-2 SARS-CoV-2 pandemic Seroconversion seroconverted spike symptom resolution the patient the SARS-CoV-2 therapy for COVID-19 transfused transfusion Viral Viral load Viral RNA was measured were assessed with mild disease [DOI] 10.3389/fimmu.2021.739037 PMC 바로가기 [Article Type] Immunology
Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patientsSARS-COV-2 브라질 감염 환자의 IgG 서브 클래스와 관련된 열성 평가Clinical Trial Published on 2021-09-032022-08-13 Journal: Scientific Reports [Category] SARS, 임상, 진단, 치료기술, [키워드] analyzed anti-RBD Anti-RBD IgG anti-RBD IgG4 antibody Antibody avidity antibody levels Antibody Response Applied immunology assessment association avidity avidity range Brazil COVID-19 detectable Diagnostic markers died disease effort elicit ELISA exacerbated Follow-up form Health highlighting hospitalized patient hospitalized patients house IgG IgG antibody IgG subclasse IgG1 IgG3 IgG4 Immunological response Immunological techniques indicate infected patient Laboratory less life-threatening Mild Mild disease Most patients outcome Patient predict protective immunity RBD RBD IgG RBD IgG-ELISA RBD protein resulting reveal SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RBD sensibility sera severe COVID-19 specificity study period symptomatic patient Symptomatic patients symptoms onset the disease Vaccine development with COVID-19 with mild disease [DOI] 10.1038/s41598-021-95045-z PMC 바로가기 [Article Type] Clinical Trial
Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure historySARS-COV-2 노출 이력에 기초한 신흥 변이체의 예방 접종 및 대리 중화에 대한 항체 반응의 내구성Comparative Study Published on 2021-08-302022-09-01 Journal: Scientific Reports [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody antibody levels Antibody Response binding booster vaccination coronavirus COVID-19 infection Decline effective Effectiveness highlighting identify indication indications Infectious diseases Messenger RNA neutralization Neutralizing antibody response neutralizing antibody responses reduced respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus symptomatic the timing vaccination Vaccine vaccine doses vaccine response vaccine responses variant variants Viral viral infection Viral variants [DOI] 10.1038/s41598-021-96879-3 PMC 바로가기 [Article Type] Comparative Study
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms급성 후 증상이 있거나 없는 COVID-19에서 회복하는 개인의 장기 SARS-CoV-2 특이적 면역 및 염증 반응Article Published on 2021-08-102022-09-11 Journal: Cell Reports [Category] MERS, SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody antibody levels CD107a CD4 CD8 coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 degranulation expressing Frequency immune immune response immune responses Immunity individual Infection Inflammation Inflammatory response initial Long COVID Lung disease magnitude marker neutralization capacity observé participant PASC PCR-confirmed peptide peptide pool Post-acute sequelae of SARS-CoV-2 infection recovering from COVID-19 respiratory Saliva SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severity Spectrum Symptom symptom onset T cell T cell response T cell responses T cells Viral viral shedding [DOI] 10.1016/j.celrep.2021.109518 PMC 바로가기 [Article Type] Article
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects건강한 대상에서 mRNA COVID-19 백신에 대한 차등 항체 반응Research Article Published on 2021-08-042022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 진단, 치료법, [키워드] Affect age age and gender anti-SARS-CoV-2 antibody antibodies antibody antibody levels Antibody Response Antigen antigens clinical study clinical utility condition Course COVID-19 COVID-19 vaccination dose feasible first and second dose Gender healthy individuals Humoral immunity immunized in healthy individual independent individual induce initial limit marker Moderna Moderna mRNA vaccine mRNA mRNA vaccines multiple antigen multiple antigens no differences not need pandemic personal health Pfizer Population postvaccination response SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection second dose specific antibodies Spike protein the antibody response the healthy the vaccine vaccination Vaccine virus-specific antibodies [DOI] 10.1128/Spectrum.00341-21 PMC 바로가기 [Article Type] Research Article
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers개별 의료 종사자의 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 항체 반응의 기간, 역학 및 결정인자Article Published on 2021-08-022022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 진단, 치료기술, 치료법, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age Analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody anti-Spike IgG anti-spike IgG levels antibody antibody half-life antibody levels Antibody Response Antibody responses Asian association Bayesian can be used Chain Reaction coronavirus coronavirus 2 COVID-19 credibility interval CrI detectable determinant Duration Dynamics estimate example faster future infection half-lives HCW HCWs healthcare worker IgG IgG level Immunity Immunoglobulin Immunoglobulin G Increasing increasing age individual interval Linear model longitudinal Longitudinal studies longitudinal study median nucleocapsid IgG polymerase chain polymerase chain reaction positive positive PCR test positive result Positive test proportion Reinfection remained required respiratory response responses risk SARS-CoV-2 self-reported symptom serology seropositive severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 survival survival analysis Symptom the mean was used were used without symptoms worker [DOI] 10.1093/cid/ciab004 PMC 바로가기 [Article Type] Article
Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults핀란드 어린이 및 성인에서 풍토성 코로나바이러스 OC43 및 229E 항체의 혈청유병률 및 SARS-CoV-2 교차 반응성Article Published on 2021-08-012022-09-11 Journal: Clinical immunology (Orlando, Fla.) [Category] MERS, SARS, 진단, 치료기술, [키워드] 229E Adults affected affecting age antibody antibody cross-reactivity antibody level antibody levels causative agents children contribute coronavirus correlated correlation cross-reactive cross-reactivity Endemic endemic HCoVs endemic human coronaviruses Finnish HCoV HCoVs human coronavirus magnitude no difference OC43 respiratory Respiratory tract infections SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2 neutralization SARS-CoV-2 pandemic sera serology Seroprevalence significantly significantly higher specific antibodies [DOI] 10.1016/j.clim.2021.108782 PMC 바로가기 [Article Type] Article
Serum antibody response to BNT162b2 after natural SARS‐CoV‐2 infection천연 SARS-CoV-2 감염 후 BNT162b2에 대한 혈청 항체 반응Observational Study Published on 2021-08-012022-09-11 Journal: European Journal of Clinical Investigation [Category] MERS, SARS, 임상, 진단, 치료법, [키워드] antibody antibody levels Antibody Response assumption benefit BNT162b2 BNT162b2 vaccine diagnostic test diagnostic tests DiaSorin dose Evidence first dose groups immunoassay in vitro individual Infection inhibition activity naïve individual naïve individuals neutralization test of BNT162b2 overlap Pfizer/BioNTech preliminary evidence receiving remained Research response Result Roche S1/S2 SARS‐CoV‐2 infection SARS‐CoV‐2 second dose serology seronegative seropositive significantly higher single dose Spike protein statistically significant stimulate supported surrogate virus neutralization test sVNT tested vaccination vaccination schedule Viral viral spike protein virus neutralization test [DOI] 10.1111/eci.13632 PMC 바로가기 [Article Type] Observational Study